mouse nerve growth factor

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cerebral Small Vessel Diseases

Conditions

Cerebral Small Vessel Diseases

Trial Timeline

Sep 7, 2019 → Feb 28, 2021

NCT ID

NCT04041349

About mouse nerve growth factor

mouse nerve growth factor is a approved stage product being developed by Sun Pharmaceutical for Cerebral Small Vessel Diseases. The current trial status is unknown. This product is registered under clinical trial identifier NCT04041349. Target conditions include Cerebral Small Vessel Diseases.

What happened to similar drugs?

4 of 16 similar drugs in Cerebral Small Vessel Diseases were approved

Approved (4) Terminated (1) Active (12)

✅RosuvastatinAstraZenecaApproved

✅clopidogrel (SR25990C)SanofiApproved

✅PiracetamUCBApproved

✅Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.Brain BiotechApproved

🔄Oral Glycopyrrolate LiquidShionogiPhase 3

🔄NXY-059AstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04041349	Approved	UNKNOWN	Sep 7, 2019	Feb 28, 2021	Cerebral Small Vessel Diseases

Competing Products

20 competing products in Cerebral Small Vessel Diseases

See all competitors

Product	Company	Stage	Hype Score
Edaravone Dexborneol + Placebo	Sun Pharmaceutical	Phase 2	31
Oral Glycopyrrolate Liquid	Shionogi	Phase 3	40
recombinant human erythropoietin alfa + 0.9% NaCl	Johnson & Johnson	Phase 2/3	38
UDI-001	Rohto Pharmaceutical	Phase 1/2	32
NXY-059	AstraZeneca	Phase 3	40
NXY-059	AstraZeneca	Phase 2	35
Rosuvastatin	AstraZeneca	Approved	39
NXY-059	AstraZeneca	Phase 3	40
Comparator: Placebo + Comparator: MK0724	Merck	Phase 2	27
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg	Merck	Phase 2	35
Recombinant Factor VIIa + Biological/Vaccine: Placebo	Novo Nordisk	Phase 3	47
Recombinant Activated Factor VII (rFVIIa) + Placebo	Novo Nordisk	Phase 3	44
Ponezumab	Pfizer	Phase 2	35
PF-05230907	Pfizer	Phase 1	21
Azithromycin + Pyrimethamine + Leucovorin calcium	Pfizer	Phase 1	29
clopidogrel (SR25990C)	Sanofi	Approved	43
Intrarectal quinine	Sanofi	Phase 3	36
Piracetam	UCB	Approved	35
Placebo + ALN-APP	Alnylam Pharmaceuticals	Phase 2	39
CN-105	Tiantan Bio	Phase 2	28